In a groundbreaking 2025 randomized trial, researchers found that once-weekly semaglutide a medication originally developed for diabetes and obesity “reduced weekly alcohol craving relative to placebo” and led to measurable declines in alcohol consum...

Markdown supported · ⌘↵ to post
No responses yet.